4-(1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methylphenyl]propyl)-2-methylphenol | 865235-93-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methylphenyl]propyl)-2-methylphenol
• 英文别名: 4-{1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-pentenyl)-3-methyl-phenyl]-propyl}-2-methyl-phenol；4-{1-ethyl-1-[4-(3-ethyl-3-hydroxy-(1E)-pent-1-enyl)-3-methyl-phenyl]-propyl}-2-methyl-phenol；4-{1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-pent-1-enyl)-3-methyl-phenyl]-propyl)-2-methyl-phenol；4-[3-[4-[(E)-3-ethyl-3-hydroxypent-1-enyl]-3-methylphenyl]pentan-3-yl]-2-methylphenol
• CAS: 865235-93-4
• 化学式: C₂₆H₃₆O₂
• 分子量: 380.571
• InChiKey: DBNPEYVEDDZLCQ-FOCLMDBBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methylphenyl]propyl)-2-methylphenol 在 1,1'-双(二苯基膦)二茂铁 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 吡啶 、 potassium acetate 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 (E)-3-ethyl-1-(4-{1-ethyl-1-[3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl) phenyl] propyl}-2-methylphenyl)-1-penten-3-ol
  参考文献：
  名称：

  VITAMIN D-LIKE COMPOUND

  摘要：

  本发明提供了一种由下列通式（I）表示的化合物： 或其药用的可接受盐，包含该化合物的药物组合物等。该化合物或其药用的可接受盐，包含该化合物的药物组合物等，用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病性肾病等的药物等。

  公开号：

  EP1894911A1
• 作为产物：
  描述：

  4-[1-ethyl-1-(4-ethynyl-3-methylphenyl)-propyl]-2-methylphenol 在 lithium aluminium tetrahydride 、 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 21.0h， 生成 4-(1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methylphenyl]propyl)-2-methylphenol
  参考文献：
  名称：

  VITAMIN D-LIKE COMPOUND

  摘要：

  本发明提供了一种由下列通式（I）表示的化合物： 或其药用的可接受盐，包含该化合物的药物组合物等。该化合物或其药用的可接受盐，包含该化合物的药物组合物等，用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病性肾病等的药物等。

  公开号：

  EP1894911A1

文献信息

• Bisphenyl compounds useful as vitamin D3 receptor agonists
  申请人：Wallace David

  公开号：US20060025474A1

  公开（公告）日：2006-02-02

  The present invention discloses bisphenyl compounds of the formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals.

  本发明公开了以下式子的双苯基化合物：其中R1，R2，R3，R4，R5，R6，X，Y，W的定义见下文。这些化合物可用作药物。
• VITAMIN-D-LIKE COMPOUNDS
  申请人：TAKAHASHI TADAKATSU

  公开号：US20110060146A1

  公开（公告）日：2011-03-10

  The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.

  本发明提供了以下一般式(I)所代表的化合物或其药学上可接受的盐，含有这种化合物的制药组合物等。该化合物或其药学上可接受的盐，含有这种化合物的制药组合物等可用作治疗良性前列腺增生、癌症、骨质疏松症、银屑病、继发性甲状旁腺功能亢进症、慢性肾小球肾炎、狼疮性肾炎和/或糖尿病肾病等药物或类似物。
• A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy
  作者：Hirotaka Kashiwagi、Yoshiyuki Ono、Masateru Ohta、Susumu Itoh、Fumihiko Ichikawa、Suguru Harada、Satoshi Takeda、Nobuo Sekiguchi、Masaki Ishigai、Tadakatsu Takahashi

  DOI：10.1016/j.bmc.2013.01.042

  日期：2013.4

  In an extension of our study on gamma hydroxy carboxylic acid analogs, we explored a series of nonsecosteroidal vitamin D receptor (VDR) agonists in which 1,3-diol of 1,25(OH)(2)D-3 had been replaced by aryl acetic acid. These analogs showed very potent activity in vitro compared with 1,25(OH)(2)D-3. An X-ray analysis of 8d showed that the inserted phenyl ring well mimicked the folded methylene linker of the gamma hydroxy carboxylic acid moiety but the carboxylic acid of 8d interacted with VDR in a different manner from gamma hydroxy carboxylic acids. Through our in vivo screening in an osteoporosis rat model using immature rats, we identified a potent active vitamin D-3 analog, compound 7e. In mature rats of the same model, compound 7e also showed good PK profiling and excellent ability to prevent bone mineral density loss without severe hypercalcemia. Our nonsecosteroidal VDR agonist 7e (CH5036249) could be a possible new drug candidate for treating osteoporosis in human. (C) 2013 Elsevier Ltd. All rights reserved.
• [EN] BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS<br/>[FR] COMPOSES DE BISPHENYLE UTILES EN TANT QU'AGONISTES DE RECEPTEURS DE LA VITAMINE D3
  申请人：CHUGAI PHARMACEUTICAL CO LTD

  公开号：WO2005087700A3

  公开（公告）日：2006-10-19
• Systematic SAR study of the side chain of nonsecosteroidal vitamin D3 analogs
  作者：Hirotaka Kashiwagi、Yoshiyuki Ono、Masateru Ohta、Kenji Morikami、Tadakatsu Takahashi

  DOI：10.1016/j.bmc.2012.05.023

  日期：2012.7

  A series of nonsecosteroidal vitamin D-3 analogs with carboxylic acid were explored. Through our systematic SAR studies on the side chain moiety, compound 6b was identified as the optimal compound showing excellent vitamin D receptor (VDR) agonistic activity. Compound 6b had the diethyl group in the terminal which was bound by (E)-olefin linker to the bisphenyl core. Calculating the volume of the side chain showed that the diethyl group in 6b filled the hydrophobic region of VDR with the ideal packing coefficient based on the 55% rule, and that this resulted in the most potent in vitro activity. (C) 2012 Elsevier Ltd. All rights reserved.